In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi bids to take the rest of Zentiva

Executive Summary

In what could become a competitive bidding situation, Sanofi-Aventis has announced its offer to acquire the remaining 75% of Czech generic drug maker Zentiva that it does not already own for €43.42 per share, or about €1.24bn ($1.9bn). The offer comes on the heels of a bid proposed in May by Czech financial institution PPF, Zentiva's second largest shareholder (to Sanofi) for €39 per share. (Zentiva's board has recommended that shareholders not accept PPF's initial offer.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies